Company News
- CTD Holdings Scientific Advisory Board Endorses Alzheimer’s Disease as Next Indication for Company’s Trappsol® Cyclo™ Drug Development Program
Jul 18, 2019, 10:24 AM EDT - CTD Obtains Right of Reference to Alzheimer’s Disease Expanded Access Data
Jul 11, 2019, 11:05 AM EDT - CTD Appoints Head of Global Regulatory Affairs
Jul 8, 2019, 8:00 AM EDT - CTD Holdings Submits Application for Listing on NASDAQ
Jun 12, 2019, 12:53 PM EDT - CTD Announces Continuation of Expanded Access Program in Single Alzheimer's Patient
Jun 10, 2019, 8:00 AM EDT - CTD Holdings Closes $7.4 Million Private Placement
May 31, 2019, 12:35 PM EDT - CTD Holdings Announces $7.2 Million Private Placement
May 30, 2019, 9:20 AM EDT - CTD Announces Home-Based Dosing of First Patient in US Extension Protocol of Clinical Trial using Intravenous Administration of Trappsol (R) Cyclo (TM) for Niemann-Pick Disease Type C
May 23, 2019, 8:00 AM EDT - CTD Announces Participation and Support for Upcoming Gathering of Patient-Support Organizations for Niemann-Pick Disease type C
May 16, 2019, 8:00 AM EDT - CTD Announces New Expanded Access Program in the United Kingdom using Trappsol(R) Cyclo(TM) Intravenously for Niemann-Pick Disease type C
May 10, 2019, 8:25 AM EDT